Taiwan's Honeybear raises $20M Series A to take cancer radiotherapy to clinic
What's the deal? Honeybear BiosciencesDealroom has a profile for this one. Try Dealroom →, a Taiwan-based precision oncology startup, has closed a $20 million Series A round led by Singapore's A*STARDealroom has a profile for this one. Try Dealroom →.
The raise brings its total funding to $34 million, one of Taiwan's largest in next-generation nuclear medicine.
The capital will push Honeybear's Antibody-Radionuclide Conjugate (ARC) therapeutics toward international clinical trials.
Why now? ARCs are seen as the next big radiopharmaceutical breakthrough, following the success of Antibody-Drug Conjugates (ADCs).
They use antibodies to deliver radiation straight to cancer cells, combining imaging and treatment in one "theranostics" approach.
Honeybear says it is the first company in Taiwan to build a full ARC platform. Its lead candidate, HB001, is in late-stage preclinical development, with an Investigational New Drug (IND) filing targeted by the end of 2026. A second candidate, HB002, should reach that stage in 2027.
What could go wrong? Both lead candidates remain preclinical, and none have yet entered human trials.
Clinical development is long, costly, and prone to failure. ARC therapies also depend on a reliable radionuclide supply chain, an area where Honeybear is still building partnerships.
The signal: The round reflects rising investor appetite for radiopharmaceuticals, with major pharma companies pouring money into the field as ARCs emerge as the next modality after Antibody-Drug Conjugates. Backing from Singapore's A*STARDealroom has a profile for this one. Try Dealroom →, a government and non-profit investor, alongside collaborations with Memorial Sloan Kettering Cancer Center and the University of California, San Francisco, signals ambitions for this early-stage company that stretch well beyond Taiwan.
Read more: GeneOnline
Image credit: IAEA Imagebank
